title: Somatostatin adjunctive therapy for non-variceal upper gastrointestinal rebleeding after endoscopic therapy.
abstract: OBJECTIVE
  To evaluate the effect of pantoprazole with a somatostatin adjunct in patients with acute non-variceal upper gastrointestinal bleeding (NVUGIB).
  
  
  METHODS
  We performed a retrospective analysis of a prospective database in a tertiary care university hospital. From October 2006 to October 2008, we enrolled 101 patients with NVUGIB that had a high-risk stigma on endoscopy. Within 24 h of hospital admission, all patients underwent endoscopic therapy. After successful endoscopic hemostasis, all patients received an 80-mg bolus of pantoprazole followed by continuous intravenous infusion (8 mg/h for 72 h). The somatostatin adjunct group (n = 49) also received a 250-μg bolus of somatostatin, followed by continuous infusion (250 μg/h for 72 h). Early rebleeding rates, disappearance of endoscopic stigma and risk factors associated with early rebleeding were examined.
  
  
  RESULTS
  Early rebleeding rates were not significantly different between treatment groups (12.2% vs 14.3%, P = 0.766). Disappearance of endoscopic stigma on the second endoscopy was not significantly different between treatment groups (94.2% vs 95.9%, P = 0.696). Multivariate analysis showed that the complete Rockall score was a significant risk factor for early rebleeding (P = 0.044, OR: 9.080, 95% CI: 1.062-77.595).
  
  
  CONCLUSIONS
  The adjunctive use of somatostatin was not superior to pantoprazole monotherapy after successful endoscopic hemostasis in patients with NVUGIB.
authors.affiliation: Department of Internal Medicine, Pusan National University School of Medicine and Medical Research Institute, Yangsan-si, Gyeongsangnam-do 626-770, South Korea.
authors.forename: Cheol Woong
authors.initials: CW
authors.lastname: Choi
authors.forename: Dae Hwan
authors.initials: DH
authors.lastname: Kang
authors.forename: Hyung Wook
authors.initials: HW
authors.lastname: Kim
authors.forename: Su Bum
authors.initials: SB
authors.lastname: Park
authors.forename: Kee Tae
authors.initials: KT
authors.lastname: Park
authors.forename: Gwang Ha
authors.initials: GH
authors.lastname: Kim
authors.forename: Geun Am
authors.initials: GA
authors.lastname: Song
authors.forename: Mong
authors.initials: M
authors.lastname: Cho
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D016208:Databases, Factual; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control* / Q000628:therapy*; D016558:Hemostasis, Endoscopic / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D012008:Recurrence; D012189:Retrospective Studies; D013004:Somatostatin / Q000627:therapeutic use*; D016896:Treatment Outcome; D041742:Upper Gastrointestinal Tract / Q000473:pathology* / Q000601:surgery*
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D013004:Somatostatin; D000077402:Pantoprazole